# EDGAR Filing Document

**Accession Number:** 0000031791
**File Stem:** 0001157523-23-000272
**Filing Date:** 2023-2
**Character Count:** 68045
**Document Hash:** 7060341a8037ca2329151e9f096ee4e7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001157523-23-000272.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001157523-23-000272

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230214

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PERKINELMER INC
- **CENTRAL INDEX KEY:** 0000031791
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **IRS NUMBER:** 042052042
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1229

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-05075
- **FILM NUMBER:** 23621852

**BUSINESS ADDRESS:**
- **STREET 1:** 940 WINTER STREET
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 781-663-5791

**MAIL ADDRESS:**
- **STREET 1:** 940 WINTER STREET
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EG&G INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EDGERTON GERMESHAUSEN & GRIER INC
- **DATE OF NAME CHANGE:** 19670626

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): February 14, 2023

------

### PerkinElmer, Inc.

#### (Exact Name of Registrant as Specified in its Charter)

------

---

| | | |
|:---|:---|:---|
| **Massachusetts**<br>| **001-05075**<br>| **04-2052042**<br>|
| **(State or Other Jurisdiction**<br> **of Incorporation or Organization)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **940 Winter Street, Waltham, Massachusetts** | **02451**<br>|
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: (781) 663-6900

#### Not applicable

#### (Former Name or Former Address, if Changed Since Last Report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |
| **Common stock, $1 par value per share<br>**  | **PKI<br>**  | **The New York Stock Exchange<br>**  |
| **1.875% Notes due 2026<br>**  | **PKI 21A<br>**  | **The New York Stock Exchange<br>**  |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 2.02. Results of Operations and Financial Condition
On February 14, 2023, PerkinElmer, Inc. announced its financial results for the fourth quarter and full year ended January 1, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

#### Item 9.01. Financial Statements and Exhibits
(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits

#### EXHIBIT INDEX

---

| | |
|:---|:---|
| Exhibit No. | **Description** |
| [99.1](a53316651ex99_1.htm)\* | [Press Release entitled "PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2022", issued by PerkinElmer, Inc. on February 14, 2023.](a53316651ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL) |

---

\* This exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.

------

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
|  | PERKINELMER, INC. |
| Date: February 14, 2023 | By: /s/ Maxwell Krakowiak |
|  | Maxwell Krakowiak<br> Senior Vice President and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**<br>

# **PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2022** 

*** **Fourth quarter revenue from continuing operations of $741 million; (28)% reported growth; (23)% organic growth; 8% non-COVID organic growth** 

* **Combined\* total fourth quarter revenue of $1,089 million; 8% combined non-COVID organic growth** 

* **Fourth quarter GAAP EPS from continuing operations of $0.85; combined adjusted EPS of $1.70** 

* **Initiates Full Year 2023 Guidance**

WALTHAM, Mass.--(BUSINESS WIRE)--February 14, 2023--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 1, 2023.

 **Fourth Quarter 2022**

The Company reported GAAP earnings per share from continuing operations of $0.85, as compared to GAAP earnings per share from continuing operations of $1.45 in the same period a year ago. GAAP revenue for the quarter from continuing operations was $741 million, as compared to $1,028 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $137 million, as compared to $300 million for the same period a year ago. GAAP operating profit margin from continuing operations was 18.5% as a percentage of revenue, as compared to 29.2% in the same period a year ago.

Adjusted operating income from continuing operations was $240 million, as compared to $432 million for the same period a year ago. Adjusted operating profit margin from continuing operations was 32.3% as a percentage of revenue, as compared to 42.0% in the same period a year ago.

Combined adjusted earnings per share for the quarter was $1.70, as compared to $2.56 in the same period a year ago. Combined adjusted revenue for the quarter was $1,089 million, as compared to $1,365 million in the same period a year ago. Combined adjusted operating income for the quarter was $298 million, as compared to $459 million for the same period a year ago. Combined adjusted operating profit margin was 27.3% as a percentage of adjusted revenue, as compared to 33.6% in the same period a year ago.

 **Full Year 2022**

The Company reported GAAP earnings per share from continuing operations of $4.13 in 2022, as compared to GAAP earnings per share from continuing operations of $7.62 in 2021. GAAP revenue from continuing operations for the year was $3,312 million, as compared to $3,828 million in 2021. GAAP operating income from continuing operations for the year was $743 million, as compared to $1,258 million in 2021. GAAP operating profit margin from continuing operations was 22.4% as a percentage of revenue, as compared to 32.9% in 2021.

Adjusted operating income from continuing operations for the year was $1,212 million, as compared to $1,637 million in 2021. Adjusted operating profit margin from continuing operations was 36.6% as a percentage of revenue, as compared to 42.7% in 2021.

------

Combined adjusted earnings per share for the year was $7.95, as compared to $11.36 in 2021. Combined adjusted revenue for the year was $4,611 million, as compared to $5,070 million in 2021. Combined adjusted operating income for the year was $1,381 million, as compared to $1,771 million in 2021. Combined adjusted operating profit margin was 30.0% as a percentage of adjusted revenue, as compared to 34.9% in 2021.

Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

\*Combined financial metrics are defined as the combination of continuing operations and discontinued operations. Discontinued operations consist of the Applied, Food and Enterprise Services (AES) businesses currently held for sale.

"2022 was an excellent year for the Company, both operationally and financially, setting us up extremely well to take the next exciting step in our corporate journey by soon separating into two standalone companies," said Prahlad Singh, president and chief executive officer of PerkinElmer. "In 2023, we enter into the next chapter in our history which will uniquely focus on providing breakthrough scientific tools to fuel our customers' development and delivery of the next generation of novel therapies and diagnostics."

 **Financial Overview by Reporting Segment for the Fourth Quarter and Full Year 2022**

 **Discovery & Analytical Solutions Continuing Operations**

* Fourth quarter 2022 revenue was $347 million, as compared to $318 million in the same period a year ago. Reported revenue increased 9% and organic revenue increased 13% as compared to the same period a year ago. 

* Full year revenue was $1,293 million, as compared to $898 million in 2021. Reported revenue increased 44% and organic revenue increased 15% as compared to 2021. 

* Fourth quarter 2022 segment operating income was $146 million, as compared to $117 million for the same period a year ago. Segment operating profit margin was 41.9% as a percentage of revenue, as compared to 36.9% in the same period a
 year ago. 

* Full year 2022 segment operating income was $503 million, as compared to $282 million in 2021. Full year segment operating profit margin was 38.9% as a percentage of revenue, as compared to 31.4% in 2021. 

 **Discovery & Analytical Solutions Combined\* Operations**

* Fourth quarter 2022 combined revenue was $695 million, as compared to $655 million in the same period a year ago. Combined revenue increased 6% and combined organic revenue increased 11% as compared to the same period a year ago. 

* Full year combined revenue was $2,591 million, as compared to $2,137 million in 2021. Combined reported revenue increased 21% and organic revenue increased 12% as compared to 2021. 

* Fourth quarter 2022 combined segment operating income was $204 million, as compared to $144 million for the same period a year ago. Combined segment operating profit margin was 29.3% as a percentage of revenue, as compared to 22.0% in
 the same period a year ago. 

* Full year combined segment operating income was $673 million, as compared to $415 million in 2021. Full year combined segment operating profit margin was 26.0% as a percentage of revenue, as compared to 19.4% in 2021. 

------

 **Diagnostics**

* Fourth quarter 2022 revenue was $394 million, as compared to $710 million for the same period a year ago. Reported revenue decreased 44% and organic revenue decreased 39% as compared to the same period a year ago. 

* Full year revenue was $2,020 million, as compared to $2,933 million in 2021. Reported revenue decreased 31% and organic revenue decreased 29% as compared to 2021. 

* Fourth quarter 2022 segment operating income was $113 million, as compared to $335 million for the same period a year ago. Segment operating profit margin was 28.7% as a percentage of revenue, as compared to 47.1% in the same period a
 year ago. 

* Full year segment operating income was $782 million, as compared to $1,433 million in 2021. Full year segment operating profit margin was 38.7% as a percentage of revenue, as compared to 48.9% in 2021. 

 **Initiates Full Year 2023 Guidance**

For the full year 2023, the Company forecasts total revenue from continuing operations of $2.94 billion and adjusted earnings per share of $5.05. This guidance assumes no contribution from COVID related revenues.

Guidance for the full year 2023 is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company's results prepared in accordance with GAAP.

 **Webcast Information**

The Company will discuss its fourth quarter and full year 2022 results and its outlook for business trends during a webcast on February 14, 2023, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company's website, ir.perkinelmer.com.

 **Use of Non-GAAP Financial Measures**

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

------

 **Factors Affecting Future Performance**

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates", "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and divestitures, such as the divestiture of the Applied, Food and Enterprise Services businesses, license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to retain key personnel; (11) significant disruption in our information technology systems, or cybercrime; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) the United Kingdom's withdrawal from the European Union; (21) our ability to obtain future financing; (22) restrictions in our credit agreements; (23) discontinuation or replacement of LIBOR; (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

 **About PerkinElmer**

PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $4.6 billion<sup>1</sup> in 2022, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

<sup>1</sup>Includes the combined revenue of continuing operations and discontinued operations <br>

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **PerkinElmer, Inc. and Subsidiaries**  | **PerkinElmer, Inc. and Subsidiaries**  | **PerkinElmer, Inc. and Subsidiaries**  | **PerkinElmer, Inc. and Subsidiaries**  | **PerkinElmer, Inc. and Subsidiaries**  |
| **CONDENSED CONSOLIDATED INCOME STATEMENTS**  | **CONDENSED CONSOLIDATED INCOME STATEMENTS**  | **CONDENSED CONSOLIDATED INCOME STATEMENTS**  | **CONDENSED CONSOLIDATED INCOME STATEMENTS**  | **CONDENSED CONSOLIDATED INCOME STATEMENTS**  |
|  | **<u>Three Months Ended</u>**  | **<u>Three Months Ended</u>**  | **<u>Twelve Months Ended</u>**  | **<u>Twelve Months Ended</u>**  |
| **(In thousands, except per share data)** | **<u>January 1, 2023</u>**  | **<u>January 2, 2022</u>**  | **<u>January 1, 2023</u>**  | **<u>January 2, 2022</u>**  |
| **Revenue** | $741214  | $1027910  | $3311822  | $3827808  |
| Cost of revenue | 304884  | 384114  | 1321992  | 1393821  |
| Selling, general and administrative expenses | 244325  | 283365  | 1025514  | 975193  |
| Research and development expenses | 54536  | 60584  | 221617  | 200337  |
| **Operating income from continuing operations** | 137469  | 299847  | 742699  | 1258457  |
| Interest income | (1565 ) | (919 ) | (3589 ) | (2241 ) |
| Interest expense | 22508  | 27721  | 103955  | 102128  |
| Change in fair value of financial securities | 1433  | (2419 ) | 15754  | (10985 ) |
| Other (income) expense, net | (23354 )  | (24240 )  | (25258 )  | (34027 )  |
| Income from continuing operations, before income taxes | 138447  | 299704  | 651837  | 1203582  |
| Provision for income taxes | 30950  | 115615  | 129161  | 314146  |
| **Income from continuing operations** | 107497  | 184089  | 522676  | 889436  |
| Income from discontinued operations, before income taxes | 37600  | 11975  | 73604  | 76304  |
| Provision for income taxes on discontinued operations and dispositions | 7439  | 5880  | 17101  | 22583  |
| **Income from discontinued operations and dispositions** | 30161  | 6095  | 56503  | 53721  |
| **Net income** | $137658  | $190184  | $579179  | $943157  |
| ***Diluted earnings per share:*** |  |  |  |  |
| Income from continuing operations | $0.85  | $1.45  | $4.13  | $7.62  |
| Income from discontinued operations and dispositions | 0.24  | 0.05  | 0.45  | 0.46  |
| Net income | $1.09  | $1.50  | $4.58  | $8.08  |
| *Weighted average diluted shares of common stock outstanding* | 126476  | 126715  | 126426  | 116674  |
| ABOVE PREPARED IN ACCORDANCE WITH GAAP  | ABOVE PREPARED IN ACCORDANCE WITH GAAP  | ABOVE PREPARED IN ACCORDANCE WITH GAAP  | ABOVE PREPARED IN ACCORDANCE WITH GAAP  | ABOVE PREPARED IN ACCORDANCE WITH GAAP  |
| **Additional Supplemental Information <sup>(1)</sup>:** |  |  |  |  |
| (per share, continuing operations) |  |  |  |  |
| GAAP EPS from continuing operations | $0.85  | $1.45  | $4.13  | $7.62  |
| Amortization of intangible assets | 0.71  | 0.77  | 2.93  | 2.20  |
| Debt extinguishment costs | (0.02 ) | -  | (0.02 ) | -  |
| Purchase accounting adjustments | 0.00  | 0.18  | 0.36  | 0.35  |
| Acquisition and divestiture-related costs | 0.11  | 0.07  | 0.32  | 0.69  |
| Change in fair value of financial securities | 0.01  | (0.02 ) | 0.12  | (0.09 ) |
| Asset impairment | -  | -  | -  | 0.03  |
| Significant litigation matters and settlements | 0.00  | 0.00  | (0.00 ) | 0.00  |
| Disposition of businesses and assets, net | (0.02 ) | -  | (0.02 ) | (0.02 ) |
| Mark to market on postretirement benefits | (0.18 ) | (0.18 ) | (0.18 ) | (0.20 ) |
| Restructuring and other, net | (0.01 ) | 0.03  | 0.11  | 0.12  |
| Tax on above items | (0.07 ) | (0.17 ) | (0.84 ) | (0.66 ) |
| Significant tax items | 0.04  | 0.29  | 0.02  | 0.44  |
| **Adjusted EPS from Continuing Operations** | **1.41**  | **2.42**  | **6.92**  | **10.49**  |
| GAAP EPS from discontinued operations | $0.24  | $0.05  | $0.45  | $0.46  |
| Amortization of intangible assets included in discontinued operations | -  | 0.06  | 0.13  | 0.29  |
| Purchase accounting adjustments | -  | 0.00  | 0.00  | 0.00  |
| Acquisition and divestiture-related costs included in discontinued operations | 0.24  | 0.07  | 0.61  | 0.20  |
| Significant litigation matters and settlements | -  | 0.00  | -  | 0.00  |
| Mark to market on postretirement benefits | (0.05 ) | (0.01 ) | (0.05 ) | (0.01 ) |
| Restructuring and other, net included in discontinued operations | (0.00 ) | (0.00 ) | 0.10  | 0.02  |
| Addback depreciation expense on assets held for sale | (0.03 ) | -  | (0.05 ) | -  |
| Tax on above items | (0.12 ) | (0.03 ) | (0.17 ) | (0.09 ) |
| Less non-AES income tax items in discontinued operations | 0.00  | 0.00  | 0.00  | 0.00  |
| **Adjusted EPS from AES** | $**0.28**  | $**0.14**  | $**1.03**  | $**0.87**  |
| **Combined Adjusted EPS including the results of AES** | $**1.70**  | $**2.56**  | $**7.95**  | $**11.36**  |
| ***(1) amounts may not sum due to rounding*** |  |  |  |  |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** |
| **REVENUE AND OPERATING INCOME (LOSS)**  | **REVENUE AND OPERATING INCOME (LOSS)**  | **REVENUE AND OPERATING INCOME (LOSS)**  | **REVENUE AND OPERATING INCOME (LOSS)**  | **REVENUE AND OPERATING INCOME (LOSS)**  |
|  | **<u>Three Months Ended</u>**  | **<u>Three Months Ended</u>**  | **<u>Twelve Months Ended</u>**  | **<u>Twelve Months Ended</u>**  |
| **(In thousands, except percentages)** | **<u>January 1, 2023</u>**  | **<u>January 2, 2022</u>**  | **<u>January 1, 2023</u>**  | **<u>January 2, 2022</u>**  |
| **Adjusted Revenue and Operating Income** |  |  |  |  |
| Reported revenue | 741214  | 1027910  | 3311822  | 3827808  |
| Revenue purchase accounting adjustments | 205  | 202  | 814  | 2648  |
| Adjusted revenue | 741419  | 1028112  | 3312636  | 3830456  |
| Reported operating income from continued operations | 137469  | 299847  | 742699  | 1258457  |
| *OP%* | *18.5* <br> *%*  | *29.2* <br> *%*  | *22.4* <br> *%*  | *32.9* <br> *%*  |
| Amortization of intangible assets | 90169  | 97923  | 370638  | 256569  |
| Purchase accounting adjustments | 87  | 22186  | 45681  | 40993  |
| Acquisition and divestiture-related costs | 13961  | 8429  | 39826  | 62760  |
| Asset impairment | -  | -  | -  | 3868  |
| Significant litigation matters and settlements | 5  | 2  | (627 ) | 2  |
| Restructuring and other, net | (1863 )  | 3841  | 13580  | 14358  |
| Adjusted operating income | 239828  | 432228  | 1211797  | 1637007  |
| *OP%* | *32.3* <br> *%*  | *42.0* <br> *%*  | *36.6* <br> *%*  | *42.7* <br> *%*  |
| **Segment Revenue and Segment Operating Income** |  |  |  |  |
| DAS | 347425  | 318498  | 1292909  | 897718  |
| Diagnostics | 393994  | 709614  | 2019727  | 2932738  |
| Revenue purchase accounting adjustments | (205 )  | (202 )  | (814 )  | (2648 )  |
| Reported revenue | 741214  | 1027910  | 3311822  | 3827808  |
| DAS | 145582  | 117388  | 503243  | 281602  |
|  | *41.9* <br> *%*  | *36.9* <br> *%*  | *38.9* <br> *%*  | *31.4* <br> *%*  |
| Diagnostics | 113004  | 334540  | 781985  | 1432769  |
|  | *28.7* <br> *%*  | *47.1* <br> *%*  | *38.7* <br> *%*  | *48.9* <br> *%*  |
| Corporate | (18758 )  | (19700 )  | (73431 )  | (77364 )  |
| Subtotal reportable segments | 239828  | 432228  | 1211797  | 1637007  |
| Amortization of intangible assets | (90169 ) | (97923 ) | (370638 ) | (256569 ) |
| Purchase accounting adjustments | (87 ) | (22186 ) | (45681 ) | (40993 ) |
| Acquisition and divestiture-related costs | (13961 ) | (8429 ) | (39826 ) | (62760 ) |
| Asset impairment | -  | -  | -  | (3868 ) |
| Significant litigation matters and settlements | (5 ) | (2 ) | 627  | (2 ) |
| Restructuring and other, net | 1863  | (3841 )  | (13580 )  | (14358 )  |
| Reported operating income from continued operations | 137469  | 299847  | 742699  | 1258457  |
| REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP  | REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP  | REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP  | REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP  | REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP  |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** |
| **REVENUE AND OPERATING INCOME (LOSS)**  | **REVENUE AND OPERATING INCOME (LOSS)**  | **REVENUE AND OPERATING INCOME (LOSS)**  | **REVENUE AND OPERATING INCOME (LOSS)**  | **REVENUE AND OPERATING INCOME (LOSS)**  |
|  | **<u>Three Months Ended</u>**  | **<u>Three Months Ended</u>**  | **<u>Twelve Months Ended</u>**  | **<u>Twelve Months Ended</u>**  |
| **(In thousands, except percentages)** | **<u>January 1, 2023</u>**  | **<u>January 2, 2022</u>**  | **<u>January 1, 2023</u>**  | **<u>January 2, 2022</u>**  |
| **Adjusted Revenue and Operating Income Combined with AES** |  |  |  |  |
| Reported revenue | 741214  | 1027910  | 3311822  | 3827808  |
| Revenue purchase accounting adjustments | 205  | 202  | 814  | 2648  |
| Adjusted revenue | 741419  | 1028112  | 3312636  | 3830456  |
| Reported operating income from continued operations | 137469  | 299847  | 742699  | 1258457  |
| *OP%* | *18.5* <br> *%*  | *29.2* <br> *%*  | *22.4* <br> *%*  | *32.9* <br> *%*  |
| Amortization of intangible assets | 90169  | 97923  | 370638  | 256569  |
| Purchase accounting adjustments | 87  | 22186  | 45681  | 40993  |
| Acquisition and divestiture-related costs | 13961  | 8429  | 39826  | 62760  |
| Asset impairment | -  | -  | -  | 3868  |
| Significant litigation matters and settlements | 5  | 2  | (627 ) | 2  |
| Restructuring and other, net | (1863 )  | 3841  | 13580  | 14358  |
| Adjusted operating income | 239828  | 432228  | 1211797  | 1637007  |
| *OP%* | *32.3* <br> *%*  | *42.0* <br> *%*  | *36.6* <br> *%*  | *42.7* <br> *%*  |
| AES reported revenue | 347554  | 336415  | 1298376  | 1239361  |
| AES reported operating income from continued operations | 31771  | 10297  | 68413  | 73921  |
| *OP%* | *9.1* <br> *%*  | *3.1* <br> *%*  | *5.3* <br> *%*  | *6.0* <br> *%*  |
| Amortization of intangible assets | -  | 7638  | 16984  | 33664  |
| Purchase accounting adjustments | -  | 295  | 6  | 295  |
| Acquisition and divestiture-related costs | 30176  | 8581  | 77212  | 23647  |
| AES depreciation addback | (3545 ) | -  | (5908 ) | -  |
| Significant litigation matters and settlements | -  | 101  | -  | 101  |
| Restructuring and other, net | (425 )  | (427 )  | 12706  | 2074  |
| AES Adjusted operating income | 57977  | 26485  | 169413  | 133702  |
| *OP%* | *16.7* <br> *%*  | *7.9* <br> *%*  | *13.0* <br> *%*  | *10.8* <br> *%*  |
| Combined reported revenue | 1088768  | 1364325  | 4610198  | 5067169  |
| Revenue purchase accounting adjustments | 205  | 202  | 814  | 2648  |
| Combined adjusted revenue | 1088973  | 1364527  | 4611012  | 5069817  |
| Combined operating income from continued operations | 169240  | 310144  | 811112  | 1332378  |
| *OP%* | *15.5* <br> *%*  | *22.7* <br> *%*  | *17.6* <br> *%*  | *26.3* <br> *%*  |
| Amortization of intangible assets | 90169  | 105561  | 387622  | 290233  |
| Purchase accounting adjustments | 87  | 22481  | 45687  | 41288  |
| Acquisition and divestiture-related costs | 44137  | 17010  | 117038  | 86407  |
| AES depreciation addback | (3545 ) | -  | (5908 ) | -  |
| Asset impairment | -  | -  | -  | 3868  |
| Significant litigation matters and settlements | 5  | 103  | (627 ) | 103  |
| Restructuring and other, net | (2288 )  | 3414  | 26286  | 16432  |
| Combined adjusted operating income | 297805  | 458713  | 1381210  | 1770709  |
| *OP%* | *27.3* <br> *%*  | *33.6* <br> *%*  | *30.0* <br> *%*  | *34.9* <br> *%*  |
| **Combined DAS Revenue and Segment Operating Income** |  |  |  |  |
| Combined DAS | 694979  | 654913  | 2591285  | 2137079  |
| Diagnostics | 393994  | 709614  | 2019727  | 2932738  |
| Revenue purchase accounting adjustments | (205 )  | (202 )  | (814 )  | (2648 )  |
| Combined revenue | 1088768  | 1364325  | 4610198  | 5067169  |
| Combined DAS | 203559  | 143873  | 672656  | 415304  |
|  | *29.3* <br> *%*  | *22.0* <br> *%*  | *26.0* <br> *%*  | *19.4* <br> *%*  |
| Diagnostics | 113004  | 334540  | 781985  | 1432769  |
|  | *28.7* <br> *%*  | *47.1* <br> *%*  | *38.7* <br> *%*  | *48.9* <br> *%*  |
| Corporate | (18758 )  | (19700 )  | (73431 )  | (77364 )  |
| Subtotal reportable segments combined with AES | 297805  | 458713  | 1381210  | 1770709  |
| Amortization of intangible assets | (90169 ) | (105561 ) | (387622 ) | (290233 ) |
| Purchase accounting adjustments | (87 ) | (22481 ) | (45687 ) | (41288 ) |
| Acquisition and divestiture-related costs | (44137 ) | (17010 ) | (117038 ) | (86407 ) |
| AES depreciation addback | 3545  | -  | 5908  | -  |
| Asset impairment | -  | -  | -  | (3868 ) |
| Significant litigation matters and settlements | (5 ) | (103 ) | 627  | (103 ) |
| Restructuring and other, net | 2288  | (3414 )  | (26286 )  | (16432 )  |
| Combined operating income from continued operations | 169240  | 310144  | 811112  | 1332378  |
| REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP  | REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP  | REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP  | REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP  | REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP  |

---

------

---

| | | |
|:---|:---|:---|
| **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** |
| **CONDENSED CONSOLIDATED BALANCE SHEETS**  | **CONDENSED CONSOLIDATED BALANCE SHEETS**  | **CONDENSED CONSOLIDATED BALANCE SHEETS**  |
| **(In thousands)** | **<u>January 1, 2023</u>**  | **<u>January 2, 2022</u>**  |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $454358  | $603320  |
| &nbsp;&nbsp;Accounts receivable, net | 612780  | 707941  |
| &nbsp;&nbsp;Inventories, net | 405462  | 425890  |
| &nbsp;&nbsp;Other current assets | 122254  | 148255  |
| &nbsp;&nbsp;Current assets of discontinued operations | 1702967  | 555374  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 3297821  | 2440780  |
| Property, plant and equipment, net | 482950  | 485531  |
| Operating lease right-of-use assets | 188351  | 164040  |
| Intangible assets, net | 3377174  | 3821847  |
| Goodwill | 6481768  | 6627119  |
| Other assets, net | 298787  | 312887  |
| Long-term assets of discontinued operations | -  | 1148350  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $14126851  | $15000554  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Current portion of long-term debt | $470929  | $4240  |
| &nbsp;&nbsp;Accounts payable | 272826  | 324811  |
| &nbsp;&nbsp;Accrued expenses and other current liabilities | 578301  | 679099  |
| &nbsp;&nbsp;Current liabilities of discontinued operations | 244448  | 205594  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 1566504  | 1213744  |
| Long-term debt | 3923347  | 4979737  |
| Long-term liabilities | 1072120  | 1422549  |
| Operating lease liabilities | 169968  | 147395  |
| Long-term liabilities of discontinued operations | 2036  | 95884  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 6733975  | 7859309  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 7392876  | 7141245  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $14126851  | $15000554  |
| PREPARED IN ACCORDANCE WITH GAAP | PREPARED IN ACCORDANCE WITH GAAP | PREPARED IN ACCORDANCE WITH GAAP |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** |
| **CONSOLIDATED STATEMENTS OF CASH FLOWS**  | **CONSOLIDATED STATEMENTS OF CASH FLOWS**  | **CONSOLIDATED STATEMENTS OF CASH FLOWS**  | **CONSOLIDATED STATEMENTS OF CASH FLOWS**  | **CONSOLIDATED STATEMENTS OF CASH FLOWS**  |
|  | **<u>Three Months Ended</u>**  | **<u>Three Months Ended</u>**  | **<u>Twelve Months Ended</u>**  | **<u>Twelve Months Ended</u>**  |
|  | **<u>January 1, 2023</u>**  | **<u>January 2, 2022</u>**  | **<u>January 1, 2023</u>**  | **<u>January 2, 2022</u>**  |
|  | (In thousands)  | (In thousands)  | (In thousands)  | (In thousands)  |
| **Operating activities:** |  |  |  |  |
| Net income | $137658  | $190184  | $579179  | $943157  |
| Income from discontinued operations and dispositions, net of income taxes | (30161 )  | (6095 )  | (56503 )  | (53721 )  |
| Income from continuing operations | 107497  | 184089  | 522676  | 889436  |
| Adjustments to reconcile income from continuing operations to net cash provided by continuing operations: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and other, net | (1863 ) | 3841  | 13580  | 14358  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 104234  | 114057  | 427000  | 311443  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 11742  | 12994  | 51518  | 29675  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension and other postretirement income | (22464 ) | (29214 ) | (23104 ) | (28509 ) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration | (608 ) | 1566  | (1377 ) | 3119  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of deferred debt financing costs and accretion of discounts | 1264  | 1738  | 7310  | 4962  |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on disposition of businesses and assets, net | (2887 ) | -  | (2887 ) | (1970 ) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of financial securities | 1433  | (2419 ) | 15754  | (10985 ) |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt extinguishment gain | (2788 ) | -  | (2880 ) | -  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired inventory revaluation | 250  | 20473  | 45289  | 35201  |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset impairment | -  | -  | -  | 3868  |
| *Changes in assets and liabilities which provided (used) cash, excluding effects from companies acquired:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | (54044 ) | (66334 ) | 66093  | 165590  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (4159 ) | 13098  | (48634 ) | 32280  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (15837 ) | 32406  | (43804 ) | (7577 ) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other | (8105 )  | 49833  | (355761 )  | (110707 )  |
| **Net cash provided by operating activities of continuing operations** | **113665**  | **336128**  | **670773**  | **1330184**  |
| **Net cash provided by (used in) operating activities of discontinued operations** | **25493**  | **(537)** <br>  | **9037**  | **80566**  |
| **Net cash provided by operating activities** | **139158**  | **335591**  | **679810**  | **1410750**  |
| **Investing activities:** |  |  |  |  |
| &nbsp;&nbsp;Capital expenditures | (26130 ) | (26954 ) | (85632 ) | (86020 ) |
| &nbsp;&nbsp;Purchases of investments | (7166 ) | (4000 ) | (47181 ) | (23130 ) |
| &nbsp;&nbsp;Proceeds from notes receivables | -  | -  | 8890  | -  |
| &nbsp;&nbsp;Proceeds from surrender of life insurance policies | -  | 109  | -  | 109  |
| &nbsp;&nbsp;Proceeds from disposition of businesses and assets | 8842  | -  | 14505  | 1460  |
| &nbsp;&nbsp;Cash paid for acquisitions, net of cash acquired | -  | (17008 )  | (7518 )  | (3982216 )  |
| **Net cash used in investing activities of continuing operations** | **(24454)** <br>  | **(47853)** <br>  | **(116936)** <br>  | **(4089797)** <br>  |
| **Net cash used in investing activities of discontinued operations** | **(1229)** <br>  | **(12097)** <br>  | **(15915)** <br>  | **(22961)** <br>  |
| **Net cash used in investing activities** | **(25683)** <br>  | **(59950)** <br>  | **(132851)** <br>  | **(4112758)** <br>  |
| **Financing Activities:** |  |  |  |  |
| &nbsp;&nbsp;Payments on borrowings | (20000 ) | (368008 ) | (240000 ) | (1559133 ) |
| &nbsp;&nbsp;Proceeds from borrowings | 20000  | 256000  | 240000  | 1400282  |
| &nbsp;&nbsp;Proceeds from term loan | -  | -  | -  | 500000  |
| &nbsp;&nbsp;Payments of term loan | -  | -  | (500000 ) | -  |
| &nbsp;&nbsp;Payments of senior debt | (50404 ) | -  | (57876 ) | (339605 ) |
| &nbsp;&nbsp;Proceeds from sale of senior debt | -  | -  | -  | 3086095  |
| &nbsp;&nbsp;Payments of debt financing costs | -  | -  | -  | (30983 ) |
| &nbsp;&nbsp;Settlement of cash flow hedges | -  | (3023 ) | (762 ) | (4482 ) |
| &nbsp;&nbsp;Settlement of swaps | -  | (14314 ) | -  | (14314 ) |
| &nbsp;&nbsp;Net payments on other credit facilities | (811 ) | (938 ) | (1292 ) | (13670 ) |
| &nbsp;&nbsp;Payments for acquisition-related contingent consideration | -  | (2208 ) | (5 ) | (2208 ) |
| &nbsp;&nbsp;Proceeds from issuance of common stock under stock plans | 7861  | 2360  | 14114  | 25120  |
| &nbsp;&nbsp;Purchases of common stock | (24501 ) | (60 ) | (80638 ) | (73072 ) |
| &nbsp;&nbsp;Dividends paid | (8841 )  | (8834 )  | (35344 )  | (32373 )  |
| **Net cash (used in) provided by financing activities of continuing operations** | **(76696)** <br>  | **(139025)** <br>  | **(661803)** <br>  | **2941657**  |
| **Net cash (used in) provided by financing activities of discontinued operations** | **-**  | **-**  | **-**  | **-**  |
| **Net cash (used in) provided by financing activities** | **(76696)** <br>  | **(139025)** <br>  | **(661803)** <br>  | **2941657**  |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 17656  | (6341 )  | (33747 )  | (22926 )  |
| **Net increase (decrease) in cash, cash equivalents, and restricted cash** | **54435**  | **130275**  | **(148591)** <br>  | **216723**  |
| Cash, cash equivalents, and restricted cash at beginning of period | 416311  | 489062  | 619337  | 402614  |
| **Cash, cash equivalents, and restricted cash at end of period** | $**470746**  | $**619337**  | $**470746**  | $**619337**  |
| **Supplemental disclosure of cash flow information:** |  |  |  |  |
| *Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:*  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $454358  | $603320  | $454358  | $603320  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash included in other current assets | 1040  | 1018  | 1040  | 1018  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash included in other assets | 349  | -  | 349  | -  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents included in current assets of discontinued operations | 14999  | 14999  | 14999  | 14999  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total cash, cash equivalents and restricted cash | $**470746**  | $**619337**  | $**470746**  | $**619337**  |
| PREPARED IN ACCORDANCE WITH GAAP  | PREPARED IN ACCORDANCE WITH GAAP  | PREPARED IN ACCORDANCE WITH GAAP  | PREPARED IN ACCORDANCE WITH GAAP  | PREPARED IN ACCORDANCE WITH GAAP  |

---

------

---

| | |
|:---|:---|
| **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** |
| **RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES <sup>(1)</sup>**  | **RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES <sup>(1)</sup>**  |
|  | **Continuing Operations**  |
|  | **Three Months Ended**  |
|  | **<u>January 1, 2023</u>**  |
| **Organic revenue growth:** |  |
| Reported revenue growth from continuing operations | -28%  |
| Less: effect of foreign exchange rates | -5%  |
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 0%  |
| &nbsp;&nbsp;Organic revenue growth from continuing operations | -23%  |
| Less: effect of COVID products | -31%  |
| &nbsp;&nbsp;Non-COVID organic revenue growth from continuing operations | 8%  |
|  | **Combined PKI**  |
|  | **Three Months Ended**  |
|  | **<u>January 1, 2023</u>**  |
| **Combined organic revenue growth:** |  |
| Reported revenue growth from continuing operations | -28%  |
| Plus: effect of discontinued operations | 8%  |
| Less: effect of foreign exchange rates | -5%  |
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 0%  |
| &nbsp;&nbsp;Combined organic revenue growth | -15%  |
| Less: effect of COVID products | -23%  |
| &nbsp;&nbsp;Combined non-COVID organic revenue growth | 8%  |
|  | **DAS**  |
|  | **Three Months Ended**  |
|  | **<u>January 1, 2023</u>**  |
| **Organic revenue growth:** |  |
| Reported revenue growth continuing operations | 9%  |
| Less: effect of foreign exchange rates | -4%  |
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 0%  |
| &nbsp;&nbsp;Organic revenue growth from continuing operations | 13%  |
|  | **Combined DAS**  |
|  | **Three Months Ended**  |
|  | **<u>January 1, 2023</u>**  |
| **Combined organic revenue growth:** |  |
| Reported revenue growth from DAS continuing operations | 9%  |
| Plus: effect of discontinued operations | -3%  |
| Less: effect of foreign exchange rates | -5%  |
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 0%  |
| &nbsp;&nbsp;Combined organic revenue growth | 11%  |
|  | **Diagnostics**  |
|  | **Three Months Ended**  |
|  | **<u>January 1, 2023</u>**  |
| **Organic revenue growth:** |  |
| Reported revenue growth continuing operations | -44%  |
| Less: effect of foreign exchange rates | -5%  |
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 0%  |
| &nbsp;&nbsp;Organic revenue growth from continuing operations | -39%  |
| ***(1) amounts may not sum due to rounding*** |  |

---

------

---

| | |
|:---|:---|
| **PerkinElmer, Inc. and Subsidiaries** | **PerkinElmer, Inc. and Subsidiaries** |
|  **RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES <sup>(1)</sup>**  | **RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES <sup>(1)</sup>**  |
|  | **DAS**  |
|  | **Twelve Months Ended**  |
|  | **<u>January 1, 2023</u>**  |
| **Organic revenue growth:** |  |
| Reported revenue growth continuing operations | 44%  |
| Less: effect of foreign exchange rates | -4%  |
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 32%  |
| &nbsp;&nbsp;Organic revenue growth from continuing operations | 15%  |
|  | **Combined DAS**  |
|  | **Twelve Months Ended**  |
|  | **<u>January 1, 2023</u>**  |
| **Combined organic revenue growth:** |  |
| Reported revenue growth from DAS continuing operations | 44%  |
| Plus: effect of discontinued operations | -23%  |
| Less: effect of foreign exchange rates | -4%  |
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 14%  |
| &nbsp;&nbsp;Combined organic revenue growth | 12%  |
|  | **Diagnostics**  |
|  | **Twelve Months Ended**  |
|  | **<u>January 1, 2023</u>**  |
| **Organic revenue growth:** |  |
| Reported revenue growth continuing operations | -31%  |
| Less: effect of foreign exchange rates | -4%  |
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 2%  |
| &nbsp;&nbsp;Organic revenue growth from continuing operations | -29%  |
| ***(1) amounts may not sum due to rounding*** |  |

---

------

 **Explanation of Non-GAAP Financial Measures**

We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

------

We use the term "adjusted revenue" to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term "adjusted revenue growth" to refer to the measure of comparing current period adjusted revenue with the corresponding period of the prior year.

We use the term "combined adjusted revenue" to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules and including revenue from the AES business reported in discontinued operations. We use the related term "combined adjusted revenue growth" to refer to the measure of comparing current period combined adjusted revenue with the corresponding period of the prior year.

We use the term "organic revenue" to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term "organic revenue growth" to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year. We use the related term "non-COVID organic revenue growth" to refer to the measure of comparing current period organic revenue excluding revenue from COVID related products and services with the corresponding period of the prior year excluding revenue from COVID related products and services.

We use the term "combined organic revenue" to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules and including revenue from the AES business reported in discontinued operations. We use the related term "organic revenue growth" to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year. We use the related term "combined non-COVID organic revenue growth" to refer to the measure of comparing current period organic revenue excluding revenue from COVID related products and services with the corresponding period of the prior year excluding revenue from COVID related products and services.

We use the term "adjusted gross margin" to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, asset impairments, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term "adjusted gross margin percentage" to refer to adjusted gross margin as a percentage of adjusted revenue.

We use the term "combined adjusted gross margin" to refer to GAAP gross margin, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, asset impairments, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term "combined adjusted gross margin percentage" to refer to combined adjusted gross margin as a percentage of combined adjusted revenue.

We use the term "adjusted SG&A expense" to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, asset impairments, and significant environmental charges. We use the related term "adjusted SG&A percentage" to refer to adjusted SG&A expense as a percentage of adjusted revenue.

------

We use the term "combined adjusted SG&A expense" to refer to GAAP SG&A expense, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, asset impairments, and significant environmental charges. We use the related term "combined adjusted SG&A percentage" to refer to combined adjusted SG&A expense as a percentage of combined adjusted revenue.

We use the term "adjusted R&D expense" to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term "adjusted R&D percentage" to refer to adjusted R&D expense as a percentage of adjusted revenue.

We use the term "combined adjusted R&D expense" to refer to GAAP R&D expense, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: excluding amortization of intangible assets and purchase accounting adjustments. We use the related term "combined adjusted R&D percentage" to refer to combined adjusted R&D expense as a percentage of combined adjusted revenue.

We use the term "adjusted net interest and other expense" to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in the value of financial securities and debt extinguishment costs.

We use the term "adjusted operating income," to refer to GAAP operating income, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms "adjusted operating profit percentage," "adjusted operating profit margin," or "adjusted operating margin" to refer to adjusted operating income as a percentage of adjusted revenue.

We use the term "combined adjusted operating income," to refer to GAAP operating income, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms "combined adjusted operating profit percentage," "combined adjusted operating profit margin," or "combined adjusted operating margin" to refer to combined adjusted operating income as a percentage of combined adjusted revenue.

We use the term "adjusted earnings per share," or "adjusted EPS," to refer to GAAP earnings per share, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding discontinued operations, amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

We use the term "combined adjusted earnings per share," or "combined adjusted EPS," to refer to GAAP earnings per share, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding discontinued operations, amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

------

Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

* *<u>Amortization of intangible assets</u>*— purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition.
 Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred. 

* *<u>Debt extinguishment costs</u>*—we incur costs and income related to the extinguishment of debt; including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and
 expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations. 

* *<u>Revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules</u>*— accounting rules require us to account for the fair value of revenue from contracts assumed
 in connection with our acquisitions. As a result, our GAAP results reflect the fair value of those revenues, which is not the same as the revenue that otherwise would have been recorded by the acquired entity. We include such revenue in our
 non-GAAP measures because we believe the fair value of such revenue does not accurately reflect the performance of our ongoing operations for the period in which such revenue is recorded. 

* *<u>Other purchase accounting adjustments</u>*—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets and deferred rent balances to fair value at the time of
 the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration
 at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent
 consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded. 

* *<u>Acquisition and divestiture-related expenses</u>*—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest expense, foreign exchange gains and losses, integration
 expenses and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations. 

* *<u>Asset impairments</u>*—we incur expense related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such
 charges were incurred. 

* *<u>Acceleration of executive compensation</u>—*the announced retirement of a senior executive resulted in an acceleration of compensation expense. We exclude these expenses from our non-GAAP measures because
 we believe they do not reflect the performance of our ongoing operations. 

* *<u>Restructuring and other charges</u>*—restructuring and other charges consist of employee severance, other exit costs as well as the cost of terminating certain lease agreements or contracts as well as
 costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported. 

* *<u>Adjustments for mark-to-market accounting on post-retirement benefits</u>*—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used
 to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our
 internal operating structure. 

* *<u>Significant litigation matters and settlements</u>*—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management
 does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred. 

* *<u>Significant environmental charges</u>*—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations
 for the periods in which such charges were incurred. 

* *<u>Disposition of businesses and assets, net</u>*—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such
 gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported. 

* *<u>Impact of foreign currency changes on the current period</u>*— we exclude the impact of foreign currency from these measures by using the prior period's foreign currency exchange rates for the current
 period because foreign currency exchange rates are subject to volatility and can obscure underlying trends. 

* *<u>Impact of significant tax events</u>*—we exclude the impact of significant tax events, such as the Tax Cuts and Jobs Act of 2017. Management does not believe the impact of significant tax events accurately
 reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded. 

* *<u>Changes in value of financial securities</u>*—we exclude the impact of changes in the value of financial securities. Management does not believe such gains or losses accurately reflect the performance of
 our ongoing operations for the period in which such gains or losses are reported. 

* *<u>Inclusion of the AES business in combined information</u>*—we report the results of the AES business in discontinued operations and include those results as a component of combined information. Management
 believes that including the results of the AES business in discontinued operations as a component of combined information increases the comparability of the financial results with historically presented results as well as recent forecasts.
 

* *<u>Depreciation of fixed assets ceased upon reporting the business as held for sale</u>*—we exclude the impact of ceasing depreciation of fixed assets that are held for sale. Management does not believe such
 charges accurately reflect the performance of our ongoing operations for the periods in which such expenses were ceased. 

------

The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board's Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, changes in the fair value of financial securities, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, restructuring and other charges, and the revenue from contracts acquired with various acquisitions is calculated based on operational results and applicable jurisdictional law, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on the average rate currently in effect to determine our tax provision.

The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

## Contacts
Investor Relations: <br> Steve Willoughby (781) 663-5677 <br> steve.willoughby@perkinelmer.com

Media: <br> Fara Goldberg (781) 663-5699 <br> fara.goldberg@perkinelmer.com